1. Home
  2. TANH vs CMMB Comparison

TANH vs CMMB Comparison

Compare TANH & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tantech Holdings Ltd.

TANH

Tantech Holdings Ltd.

N/A

Current Price

$12.51

Market Cap

8.2M

Sector

N/A

ML Signal

N/A

CMMB

Chemomab Therapeutics Ltd.

N/A

Current Price

$1.38

Market Cap

8.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TANH
CMMB
Founded
2001
2004
Country
China
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.2M
8.4M
IPO Year
2013
2023

Fundamental Metrics

Financial Performance
Metric
TANH
CMMB
Price
$12.51
$1.38
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $15.00
AVG Volume (30 Days)
★ 124.8K
29.6K
Earning Date
12-18-2026
11-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 101.67
EPS
N/A
★ 0.04
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ $0.17
$30.75
Revenue Growth
N/A
N/A
52 Week Low
$0.20
$0.92
52 Week High
$29.89
$2.99

Technical Indicators

Market Signals
Indicator
TANH
CMMB
Relative Strength Index (RSI) 48.27 47.38
Support Level $12.62 $0.99
Resistance Level $18.29 $1.91
Average True Range (ATR) 4.12 0.13
MACD -0.18 0.06
Stochastic Oscillator 24.16 84.44

Price Performance

Historical Comparison
TANH
CMMB

About TANH Tantech Holdings Ltd.

Tantech Holdings Ltd manufactures bamboo charcoal-based products. The company, through its subsidiaries, is engaged in the production and distribution of household products along with a trading business, which involves the export of charcoal products. It also manufactures electric double-layer capacitors carbon materials and low-emission barbecue charcoal. Its product portfolio includes air purifiers and humidifiers, underfloor humidity control, pillows and mattresses, wardrobe deodorizers, mousepads, and wrist mats, refrigerator deodorant, and charcoal toilet cleaner disks.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

Share on Social Networks: